Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

The Oracle announced a quarterly dividend

9/12/23 ORCL

Globaltrans registered the prospectus of receipts with the Bank of Russia

9/12/23 GLTR

M.Video-Eldorado to present new development strategy in 2024

9/11/23 MVID

X5 Retail Group will open its first stores in the Amur and Jewish Autonomous Regions

9/11/23 FIVE

Moscow Exchange will suspend trading of VK receipts for the period of redomiciliation

9/11/23 VKCO

Investment in Vostok Oil is estimated at ₽12 trillion

9/11/23 ROSN

Aeroflot in August increased transportation by 7.5%

9/11/23 AFLT

Polyus plans to launch production at Chulbatkan in 2029-2030

9/11/23 PLZL

Skillbox consolidates 100% of online school Skillfactory

9/11/23 VKCO

M.Video-Eldorado expects net debt/EBITDA to fall below 4x

9/11/23 MVID